Hyperphosphatemia

Dialysis Patients Struggle to Restrict Dietary Phosphorus

By

The increasing popularity of processed convenience foods could be a factor.

Heart Abnormality Tied to High Dietary Phosphorus Intake

By

Consuming too much phosphorus increases the risk of left ventricular hypertrophy in women, study finds

Intradialytic High Protein Meals May Correct Low Albumin

By

Combined with use of a binder, this approach raised serum albumin while maintaining target phosphorus levels.

Low BMI, Lipid Abnormalities Linked to High FGF-23

By

Factors unrelated to mineral metabolism may contribute to the association between high FGF-23 and death in dialysis patients.

High Phosphorus Levels Increase Renal Failure Risk

By

Researchers made the discovery in a study of individuals with normal kidney function.

Hyperphosphatemia Raises Proteinuria Risk in CKD Patients

By

Proteinuria also is linked to high cholesterol.

Higher Phosphate Reduces VLPD Anti-Proteinuric Response

By

Reducing phosphate burden may decrease proteinuria and slow progression of renal disease in patients with chronic kidney disease.

Side Effects Cited for Many Binder Discontinuations

By

Nearly 11% of hemodialysis (HD) patients who discontinued use of a phosphate binder did so because of side effects.

Sodium Bicarbonate Lowers Phosphorus in PD Patients

By

Oral sodium bicarbonate may ease hyperphosphatemia in peritoneal dialysis (PD) patients with metabolic acidosis.

Phosphorus and Disease Progression in Autosomal Dominant Polycystic Kidney Disease

By

Dietary phosphorus may have an effect on the progression of autosomal dominant polycystic kidney disease.

Phosphorus Levels Lower in Elderly HD Patients

By

Serum phosphorus concentrations are significantly lower in elderly hemodialysis (HD) patients compared with younger patients.

Give Priority to Phosphate Control, Researchers Conclude

By

Phosphate level is a stronger predictor for increased mortality among hemodialysis (HD) patients than calcium and parathyroid hormone (PTH) levels.

Phosphate Binder, Phosphate Diet Act Synergistically

By

Lanthanum carbonate acts in synergy with dietary phosphate restriction to decrease levels of fibroblast growth factor 23 (FGF-23) in patients with chronic kidney disease (CKD) and normal phosphate levels.

Higher Phosphate, PTH Predict Worse Outcomes

By

Hyperparathyroidism develops prior to significant hyperphosphatemia in patients with chronic kidney disease (CKD) but not on dialysis.

Optimal Levels of PTH and Phosphorus Defined

By

New findings presented at Kidney Week 2012 suggest that target serum phosphorus levels in patients on maintenance hemodialysis (MHD) may need to be defined.

High iPTH Raises Hyperphosphatemia Risk

By

High serum levels of (iPTH) and dietary protein intake are associated with an increased risk of hyperphosphatemia in patients on MH.

CKD Complications Linked to BMI, Waist Size

By

Greater body mass index and waist circumference increases risk of secondary hyperparathyroidism, hyperphosphatemia, and hypertension.

Effect of Phosphate Binders in Chronic Kidney Disease Unclear

Effect of Phosphate Binders in Chronic Kidney Disease Unclear

Linked to lower urinary, serum phosphorus, but promote progression of vascular calcification

Elevated FGF-23 Linked to Insulin Resistance

By

An unexpected impact may be excessive phosphorus retention.

Hyperphosphatemia Linked to Diuretic Use

By

PARIS—Diuretics may raise phosphate levels and increase the likelihood of hyperphosphatemia in patients with chronic kidney disease.

Raising Lanthanum Dose Cuts Phosphorus Levels

By

PARIS—Raising the dose of the calcium-free phosphate binder lanthanum carbonate from a lower conventionally used dose of 2,250 or less to 3,000 mg/day may reduce phosphorus levels in patients with chronic kidney disease (CKD) and hyperphosphatemia.

Novel Iron-Based Phosphate Binder Effective, Well-Tolerated

By

NATIONAL HARBOR, Md.—An investigational iron-based phosphate binder is effective and well tolerated in hemodialysis (HD) patients with hyperphosphatemia, according to data presented at the National Kidney Foundation 2012 Spring Clinical Meetings.

Novel Tool May Help Dialysis Patients with Phosphorus Control

By

LAS VEGAS—A novel interactive Web-based phosphorus education tool may help to improve phosphorus control in dialysis patients, according to a report at the National Kidney Foundation's Spring Clinical Meetings.

Hyperphosphatemia and Anemia Risk Factors in Diabetic Nephropathy Patients

By

LAS VEGAS—Albumunuria, proteinuria, lower estimated glomerular filtration rate (eGFR) in patients with diabetic nephropathy are significantly associated with hyperphosphatemia and anemia, researchers reported at the National Kidney Foundation's Spring Clinical Meetings.

Study Finds No Link Between FGF-23 and Dietary Phosphorus

By

LAS VEGAS—Fibroblast growth factor 23 (FGF-23) is not significantly associated with dietary phosphorus or urinary phosphorus excretion, researchers reported at the National Kidney Foundation's Spring Clinical Meetings.

Lanthanum Carbonate Found to Bind Dietary Phosphorus Better than Sevelamer

By

LAS VEGAS—Lanthanum carbonate binds dietary phosphorus more effectively than sevelamer, researchers reported here at the National Kidney Foundation's Spring Clinical Meetings.

CKD Stage 3 Patients Benefit from Extended-Release Niacin

By

LAS VEGAS—New findings presented at the National Kidney Foundation's Spring Clinical Meetings confirm the phosphorus-lowering effects of extended-release niacin in fixed-dose combination with laropiprant (ERN-L) in dyslipidemic patients with stage 3 chronic kidney disease (CKD).

Crushed Lanthanum Carbonate an Option for HD Patients

By

Crushing lanthanum carbonate and mixing it with food can be an option for hemodialysis (HD) patients with hyperphosphatemia who are unable to chew or swallow whole tablets, researchers reported in Hemodialysis International (2011;15:95-99).

Novel Binder Lowers Phosphorus, LDL Cholesterol

By

An investigational calcium-free phosphate binder called colestilan is safe and effective for controlling phosphorus in dialysis patients, and it has no impact on calcium levels, researchers reported.

Parathyroid Hormone, Alkaline Phosphatase and Fibroblast Growth Factor 23

Parathyroid Hormone, Alkaline Phosphatase and Fibroblast Growth Factor 23

The management of chronic kidney disease-mineral bone disorder (CKD-MBD) is central to the care of patients with kidney disease. Key to these efforts is the availability of clinically accessible biomarkers that can help distinguish between a wide variety of bone and mineral disturbances related to kidney failure.